Navigation Links
The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
Date:12/5/2011

NEW YORK, Dec. 5, 2011 /PRNewswire/ -- Levi & Korsinsky is investigating potential claims on behalf of purchasers of the securities of Pacific Biosciences of California, Inc. ("PacBio" or the "Company") (NASDAQ: PACB) concerning possible violations of federal securities laws.

For more information, click here: http://zlk.9nl.com/pacific-biosciences-california-pacb/.

The investigation stems from allegations that the Company failed to disclose the following: (a) that contrary to the Company's claim that the RS system its used for DNA sequencing had a 'market dominating' 99.3 percent base calling accuracy rate, the system's raw-read accuracy rate was in fact between 80 and 84 percent; (b) that as a result of PacBio's inefficient RS system, potential customers would be forced to sacrifice long read length time to obtain increased raw-read accuracy in DNA sequencing; (c) that numerous bugs and flaws in PacBio's RS system caused it to crash frequently; and (d) owing to the aforementioned problems, PacBio's RS system was receiving significant negative feedback.

On September 21, 2011, PacBio disclosed that its operations were threatened by the Company's cash burn and, as a result, the Company would lay off 130 employees and would incur $5 million in related separation expenses.  In reaction to this news, PacBio stock plummeted 25% to close at $4.25 per share.

If you own PacBio stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pacific-biosciences-california-pacb.html.

Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 15th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

 


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
2. Elsevier Announces Availability of Urban & Fischer Journal Archives on SciVerse ScienceDirect
3. Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care
4. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
5. S&P Capital IQ Picks Celgene Focus Stock of the Week
6. Sandell Asset Management Seeks Sale of Rubicon & Tenon, Expansion of Board
7. Wound Management Technologies to Present at AdvaMed 2011; Conferences Featured Speakers to Include President George W. Bush & HHS Secretary Kathleen Sebelius
8. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
9. Building, Validating & Maintaining Controlled Environment Facilities is Focus of Oct. 18th Seminar in Boston Hosted by Microtest Laboratories
10. Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research
11. Palatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... host a Key Opinion Leader event to highlight new ... and poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology ... event will be held in-person and via live webcast ... 9:00 AM PST at the Lotte New York Palace ...
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight Against ... Cancer Research (OICR) are pleased to report that Fusion ... financing, with Johnson & Johnson Innovation – JJDC, Inc. ... venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, ... ...
Breaking Biology Technology:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
Breaking Biology News(10 mins):